AM vs REGN · P/E 25, rev $1.11B vs P/E 14, rev $14.34B
Antero Midstream Partners LP (AM) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Antero Midstream Partners LP (AM) is a oil & gas midstream company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported AM revenue for 2024-12-31 was $1.11B. Net income was $400.9M. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. AM currently screens at market cap $10.19B and trailing P/E 24.9.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
AM currently screens at market cap $10.19B and trailing P/E 24.9. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the AM and REGN stock pages for the full models.
Not investment advice.